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Received 25 April 1979 ALTHOUGH serum ferritin concentration usually reflects body iron stores in patients with iron deficiency and overload (Addison et at., 1972) , the relationship is lost in a variety of pathological conditions. Hyperferritinaemia without iron overload occurs with chronic inflammation (Zucker et al., 1974) , in acute and chronic liver disease (Martin et al., 1971; Prieto et al., 1975) and in a variety of human malignancies including breast cancer (Buffe et al., 1968; Jones et al., 1973; Niitsu et al., 1975; Mori et al., 1975; Marcus & Zinberg, 1975) , suggesting that serum ferritin may have a role as a tumour index substance. In this respect, it has been suggested that measurement of serum ferritin concentration may be useful in the follow-up of patients with certain malignancies, to help assess residual tumour mass (Wahren et al., 1977) . Whilst studying patients with breast cancer undergoing treatment, we noticed that, contrary to expectation, the concentration of serum ferritin often increased in the immediate postoperative period. This stimulated a more detailed study of serum ferritin concentration around the operative period in patients with breast cancer.
Fifty (Hazard & Drysdale, 1977) . This study used antibody raised against human liver isoferritins but it would not differentiate between tumour and normal tissue ferritin.
The preoperative hyperferritinaemia found in patients in this study could represent tumour secretion of ferritin, and it is possible that the significant postoperative fall in serum ferritin concentration is due to reduction of the tumour mass, but the possibility that removal of inflammatory tissue is a cause cannot be excluded. In this respect, serum ferritin concentration has also been shown to be raised in patients with infection and to fluctuate with disease activity in juvenile chronic polyarthritis (Craft et al., 1977) , thus behaving like other acutephase reactant proteins such as fibrinogen and haptoglobin. This would explain the rise in serum ferritin concentration in the postoperative period, ferritin being released from normal tissues in response to surgery. This would be supported by the bigger rise in Group A patients than in Group B, who may be considered to have an already established inflammation causing the preoperative hyperferritinaemia.
We have demonstrated a raised serum ferritin concentration preoperatively in 21/50 (42%) of patients with breast cancer without detectable systemic metastasis, and a significant postoperative rise in 90% of patients studied, although we are unsure of the cause. The effect of surgery indicates that specimens taken in the immediate postoperative period may give inflated values and emphasizes the need for caution in interpreting serum ferritin concentration measured with an anti-liver ferritin antibody, in both the assessment of body iron stores and as a measure of tumour mass. The development of a more specific assay for the tumour ferritin in question might answer some questions raised by these data.
